Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with IN/I-Dimethylnitros...
Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with IN/I-Dimethylnitrosamine-Induced Liver Cirrhosis
About this item
Full title
Author / Creator
Publisher
MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
MDPI AG
Subjects
More information
Scope and Contents
Contents
Tofacitinib, a Janus kinase 1 and 3 inhibitor, is used to treat rheumatoid arthritis. It is mainly metabolized by the cytochromes p450 (CYP) 3A1/2 and CYP2C11 in the liver. Chronic inflammation eventually leads to cirrhosis in patients with rheumatoid arthritis. Isosakuranetin (ISN), a component of Citrus aurantium L., has hepatoprotective effects...
Alternative Titles
Full title
Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with IN/I-Dimethylnitrosamine-Induced Liver Cirrhosis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A746374612
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A746374612
Other Identifiers
ISSN
1999-4923
E-ISSN
1999-4923
DOI
10.3390/pharmaceutics14122684
